Evgen Pharma plc is a United Kingdom-based clinical-stage drug development company. The Company is focused on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. The Company’s core technology is Sulforadex, which is a method for synthesizing and stabilizing the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. Its asset, SFX-01, is a composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive metastatic breast cancer. SFX-01 exploits sulforaphane’s activity in three separate biochemical pathways, such as inhibition of STAT3 and SHP2, of importance in controlling cancers metastases, and up-regulation of Nrf2, a pathway of significance in several different diseases. Its pipeline includes breast cancer, glioblastoma, hematological malignancies, and analogues. It also has a licensing in neurodevelopmental disorders and schizophrenia.